Dr. Munver on mitomycin gel for low-grade UTUC

Video

“Mitomycin gel, or Jelmyto, is the first agent that gives us a chance to be able to treat these low-grade upper tract cancers of the ureter and the kidney and prevent their recurrence,” says Munver.

Ravi Munver, MD, vice chairman, chief, Minimally Invasive and Robotic Urologic Surgery, Department of Urology, Hackensack University Medical Center, discusses the treatment breakthrough of mitomycin gel (Jelmyto) as a therapy for patients with low-grade upper tract urothelial carcinoma.

Related Videos
Scott T. Tagawa, MD, MS, FACP, FASCO, an expert on bladder cancer
Scott T. Tagawa, MD, MS, FACP, FASCO, an expert on bladder cancer
Scott T. Tagawa, MD, MS, FACP, FASCO, an expert on bladder cancer
Scott T. Tagawa, MD, MS, FACP, FASCO, an expert on bladder cancer
Scott T. Tagawa, MD, MS, FACP, FASCO, an expert on bladder cancer
Scott T. Tagawa, MD, MS, FACP, FASCO, an expert on bladder cancer
Scott T. Tagawa, MD, MS, FACP, FASCO, an expert on bladder cancer
Scott T. Tagawa, MD, MS, FACP, FASCO, an expert on bladder cancer
Dr. Kyle A. Richards in an interview with Urology Times
3d rendered illustration - bladder cancer | Image Credit: © SciePro - stock.adobe.com
Related Content
© 2023 MJH Life Sciences

All rights reserved.